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The Erns glycoprotein of classical swine fever virus (CSFV) has been studied in detail concerning
biochemical and functional properties, whereas less is known about its antigenic structure.
In order to deﬁne epitopes recognized by CSFV-speciﬁc antibodies, the binding sites of seven Erns-
speciﬁc monoclonal antibodies were investigated. Mapping experiments using chimeric Erns proteins,
site-directed mutagenesis and an overlapping peptide library identiﬁed one antigenic region located
between amino acids (aa) 55 to 110 on the Erns protein of CSFV Alfort/187. The domain comprises three
linear motifs *64TNYTCCKLQ72, 73RHEWNKHGW81, and 88DPWIQLMNR96, respectively, and two aa at
position 102 and 107 that are crucial for the interaction with antibodies. Additionally, the presentation
of the epitope in a correct conformation is mandatory for an efﬁcient antibody binding. These ﬁndings
allow a better understanding of the organization and the structure of the Erns and provide valuable
information with regard to the development of Erns-based diagnostic tests.
& 2012 Elsevier Inc. All rights reserved.Introduction
Classical swine fever virus (CSFV) is an enveloped positive-
stranded RNA virus belonging to the genus Pestivirus within the
family Flaviviridae. It is the causative agent of classical swine fever
(CSF), a highly contagious disease in domestic pigs and wild boar.
The virus is structurally and antigenetically closely related to the
ruminant bovine viral diarrhea virus (BVDV) and Border disease
virus (BDV) which are also members of the genus Pestivirus. Based
on phylogenetic analysis, CSFV can be divided into three geno-
types each comprising three to four subgenotypes (Paton et al.,
2000; Postel et al., 2012). In previous studies using panels of
monoclonal antibodies it could further be shown, that the
different strains display not only genetic, but also antigenicll rights reserved.
e (D. Meyer),
talstr. 32, CH-3063 Ittigen,diversity (Kosmidou et al., 1995). CSFV possesses a 12.3 kb
genome encoding a single polyprotein precursor that is processed
into the four structural proteins C, Erns, E1, and E2 and seven to
eight non-structural proteins, namely Npro, p7, NS2, NS3/NS2-3,
NS4A, NS4B, NS5A, and NS5B (Lindenbach and Rice, 2001).
The Erns protein forms a disulﬁde-linked homodimer of
approximately 97 kDa with more than 50% of the molecular mass
contributed by carbohydrates (Ru¨menapf et al., 1993). Its protein
structure is stabilized by four conserved intramolecular disulﬁde
bridges (Langedijk et al., 2002). Association with the viral envel-
ope membrane is mediated via the C-terminus that represents an
amphipathic helix (Fetzer et al., 2005; Tews and Meyers, 2007). In
addition to its function as an envelope-associated structural
protein, Erns is secreted from CSFV-infected cells as a soluble
protein (Ru¨menapf et al., 1993). Another unique feature of the Erns
protein is its intrinsic RNase activity caused by two catalytic
active sites displaying homology with members of the Rh/T2/S
RNase superfamily (Hausmann et al., 2004; Hulst et al., 1994;
Schneider et al., 1993; Windisch et al., 1996). Together with the
envelope glycoprotein E2, Erns is capable to elicit neutralizing
antibody responses conferring protective immunity (Ko¨nig et al.,
1995; Weiland et al., 1992; Weiland et al., 1990). Thus, serological
diagnosis of CSF is mainly based on the detection of E2- or Erns-
speciﬁc antibodies (Clavijo et al., 2001; Colijn et al., 1997;
Moormann et al., 2000; Moser et al., 1996).
Fig. 1. Immunoblot analysis under reducing and non-reducing conditions. Cell
lysates (3 mg protein per slot) were analyzed using a 10% (v/v) acrylamide
resolving gel. For the detection of the Erns protein mAb HC/TC57 was used. Cell
lysates of non transfected BSR-T7/5 cells were used for the cell control. An
antibody against a-tubulin served as a loading control.
Table 1
Reactivity of mAbs with the native and chimeric Erns proteins in the PLA.
Native and chimeric Erns
proteins
mAb HC/TC BVD/
C12
126 56 57 58 61 66 69 169
Alfort/187 Erns þþ þþ þþ þþ þþ þþ þþ þþ 
NADL Erns (þ) (þ) (þ) (þ) (þ)  (þ) þþ þþ
AR4 þþ þþ þþ þþ þþ þþ þþ þþ þþ
AR5 (þ) (þ) (þ) (þ) (þ)  (þ) þ þþ
AR6 þþ þþ þþ þþ þþ þþ þþ þþ 
AR7 þþ þþ þþ þþ þþ þþ þþ þþ 
AR8 þþ þþ þþ þþ þþ þþ þþ þþ þþ
Non-transfected cells         
þþ, strong reactivity; þ , moderate reactivity; (þ), weak reactivity;  , no
reactivity.
D. Meyer et al. / Virology 433 (2012) 45–5446Even though the Erns protein has been well characterized con-
cerning its biochemical and functional properties, less is known about
its antigenic structure. Based on Escherichia coli surface display of
CSFV gene-derived random peptide libraries and Erns-speciﬁc mono-
clonal antibodies (mAbs) two overlapping peptide sequences
114CRYDKNTDVNV124 and 116YDKNTDVNV124 were identiﬁed as
epitopes and could be conﬁrmed in a later study by using a phage
display peptide library (Christmann et al., 2001; Zhang et al., 2006).
Using bacterially expressed truncated Erns proteins three overlapping
antigenic regions (Asn65–Ser145; Trp84–Ser160; Glu109–Lys220) were
shown to react with sera from CSFV-infected pigs (Lin et al., 2005; Lin
et al., 2004). Peptides comprising the 37 C-terminal amino acid (aa)
residues of Erns revealed immunogenic properties when applied as
ELISA antigens (Langedijk et al., 2001). Recently, ﬁve groups of linear
epitopes recognized by Erns-speciﬁc mAbs were deﬁned and char-
acterized using overlapping peptide libraries and phage display (Lin
et al., 2010).
However, for the development of novel Erns-based diagnostic
tests a comprehensive knowledge on the antigenic topology of the
Erns as well as the characterization of new Erns-speciﬁc mAbs is
required. Erns-based immunoassays are of special interest with
regard to a future application of CSF marker vaccines within the
European Union. In order to enable prophylactic and emergency
vaccination against CSF, new generations of marker vaccines have
been developed that provide a fast protection combined with the
possibility to differentiate between infected and vaccinated ani-
mals (DIVA). The most promising vaccine candidate is the
chimeric pestivirus CP7_E2alf, which is based on the BVDV-1
strain CP7 expressing the E2 protein of CSFV strain Alfort/187
(Koenig et al., 2007; Reimann et al., 2004). The accompanying
DIVA principle is based on the detection of CSFV Erns-speciﬁc
antibodies that are raised upon CSFV infection but not after
marker vaccine application.
In the present study chimeric Erns proteins were used to gain
new insights into the antigenic structure of the CSFV Erns protein
and to characterize Erns-speciﬁc mAbs. According to the mAb
reactivity with chimeric Erns proteins an antigenic domain was
identiﬁed between amino acids (aa) 55 to 110 which was then
analyzed in more detail by using CSFV Erns mutants and an
overlapping peptide library.
The obtained data contribute to a better understanding of the
antigenic structure of the Erns protein and are therefore important
for the development of novel Erns-based diagnostic tools.Results
Immunoblots under reducing and non-reducing conditions
The reactivity of the mAbs with the full-length Erns protein of
CSFV Alfort/187 was analyzed in immunoblots under reducing
and non-reducing conditions. Under non-reducing conditions the
monomeric as well as the dimeric form of the Erns were detected
by the mAbs. However, the reactivity was abolished using redu-
cing conditions. Results obtained with one representative mAb
(HC/TC57) are shown in Fig. 1. The detection of the cellular
protein a-tubulin was used as a loading control.
Epitope mapping with chimeric Erns proteins
The chimeric proteins AR4, AR5, AR6, AR7, and AR8 were
generated in order to determine immunodominant regions on the
correctly folded CSFV Erns protein. Different parts of the Erns
protein of the CSFV strain Alfort/187 were replaced by corre-
sponding parts of the BVDV-1 strain NADL. This BVDV strain was
selected because except for the control mAb HC/TC169, none ofthe CSFV-speciﬁc mAbs detected the NADL Erns protein in pre-
vious infection studies (data not shown).
The reactivity with seven CSFV Erns-speciﬁc mAbs was ana-
lyzed 20 h after transfection of the respective recombinant
plasmid in BSR-T7/5 cells using PLA. All mAbs were able to detect
the wild type Alfort/187 Erns in transfected cells (Table 1). As an
additional control to monitor the BVDV-speciﬁc Erns protein
expression the mAb BVD/C12 was used. The chimeric proteins
AR4, AR6, and AR7 were detected by all CSFV-speciﬁc mAbs.
They share the aa sequence between position 55 to 110 (Fig. 5).
The mAbs HC/TC126, HC/TC56, HC/TC57, HC/TC58, HC/TC61, and
HC/TC69 only weakly reacted with the AR5 chimera. In contrast,
the control mAbs BVD/C12 and HC/TC169 detected this chimera
with an efﬁciency comparable to their respective wild type Erns
proteins (Table 1). These results indicated that the region
between residues 55 to 110 within the Erns protein of CSFV strain
Alfort/187 is recognized by Erns-speciﬁc antibodies. Hence, a
chimeric protein (AR8) was generated based on the BVDV-1 NADL
Erns in which residues 55 to 110 were replaced by the correspond-
ing aa of the CSFV strain Alfort/187. All mAbs detected the AR8
chimera with similar reactivity as the wild type Alfort/187 Erns
protein (Table 1).
Analysis of Erns exchange mutants
Protein sequence analysis revealed that the region between
aa 55 to 110 is well conserved both, among pestivirus species and
among different strains of CSFV (Fig. 2). However, some posi-
tions display natural variations. To investigate the inﬂuence of
these aa differences on the binding of antibodies, site-directed
Fig. 2. Sequence alignment of Erns proteins encoded by selected strains of CSFV, BVDV, and BDV. Amino acids that are matching those of CSFV Alfort/187 are indicated by
dots. The antigenic domain (aa 55–110) deﬁned by binding analysis with chimeric pestivirus proteins is marked with a red box and the aa targeted for site-directed
mutagenesis are highlighted in red. The ten linear epitope determinants identiﬁed by using the peptide library are colored in grey.
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105, and 107 were selected for the generation of exchange
mutants. For this purpose, aa of the Erns protein of the CSFV strain
Alfort/187 were replaced by the corresponding aa of the CSFV
isolate CSF0849 or the BVDV-1 strain NADL and vice versa (Fig. 2).
Both, the CSFV strain as well as the BVDV strain, display sequence
variations at the afore mentioned mutation sites. In addition,
none of the CSFV-Erns speciﬁc mAbs (with exception of control
antibody HC/TC169) detected the NADL Erns or the CSF0849 Erns in
previous infection studies (data not shown).
The reactivity of the CSFV-speciﬁc mAbs with Erns mutants was
analyzed in the immunoblot under non-reducing conditions. All
wild type and mutated Erns proteins were detected by mAb HC/
TC169 as the monomeric (40 kDa) and dimeric form (95 kDa)
(Fig. 3). Therefore, this mAb was used as a control for the protein
expression of the modiﬁed Alfort/187 and CSF0849 Erns proteins
(Fig. 3a and b). The mAb BVD/C12 was added to control the
expression of the NADL Erns proteins (Fig. 3c). According to the
reactivity pattern with the mutated proteins, two antibody
groups could be distinguished besides HC/TC169 (Table 2). The
ﬁrst group contains the mAbs HC/TC126, HC/TC66, and HC/TC69.
These antibodies reacted equally with the wild type Alfort/187
Erns and the mutated Alfort/187 ErnsQ55P protein. Mutations
introduced at positions 102 (Alfort/187 ErnsA102T) and 107
(Alfort/187 ErnsA107D) caused a reduced reactivity. With the
double mutated protein Alfort/187 ErnsA102T/A107D thereactivity was completely abolished (Table 2, Fig. 3). Whereas
none of these three mAbs was able to bind the wild type Erns
protein of the CSFV isolate CSF0849, analysis of exchange mutants
showed contrary results. Mutations introduced at positions 102
(CSF0849 ErnsT102A) or 107 (CSF0849 ErnsD107A), respectively,
led to the detection of the Erns protein (Table 2, Fig. 3).
All mAbs among the ﬁrst group were able to detect the double
mutant NADL ErnsT102A/D107A (Table 2, Fig. 3). Additionally, the
mAb HC/TC126 was able to bind the mutant NADL ErnsT102A
(Table 2).
The remaining mAbs HC/TC56, HC/TC57, HC/TC58, and HC/
TC61 could be classiﬁed in a second group. In contrast to the
mAbs of group one, they did not detect the mutants Alfort/187
ErnsA107D and CSF0849 ErnsT102A (Table 2, Fig. 3). However, they
showed a positive reaction with the mutants NADL ErnsT102A and
NADL ErnsT102A/D107A (Table 2, Fig. 3). The mutation introduced
at position 105 in the NADL Erns had no inﬂuence on the reactivity
with the seven CSFV-Erns speciﬁc mAbs (Table 2, Fig. 3).
Epitope mapping using overlapping peptides
To determine epitope motifs within the deﬁned antibody
binding site aa 55 to 110, an overlapping peptide library was
used. A peptide membrane representing the complete CSFV Erns
protein was incubated consecutively with the seven CSFV Erns-
speciﬁc mAbs and three CSFV antibody-positive antisera. The
Fig. 3. Detection of the mutated Alfort/187 (A), CSF0849 (B), and NADL (C) Erns
proteins in the immunoblot (monomeric Erns¼40 kDa; homodimeric
Erns¼95 kDa). Cell lysates (7.5 mg protein per slot) were analyzed under non-
reducing conditions using a 10% (v/v) acrylamide resolving gel. For the detection
of the Erns proteins, the mAbs HC/TC61 (group 1) and HC/TC66 (group 2) were
used. To monitor the expression of the Alfort/187 and CSF0849 Erns constructs, the
immunoblot was stained with the mAb HC/TC169. For the NADL Erns constructs
the mAb BVD/C12 was used. Cell lysates of non transfected BSR-T7/5 cells were
used for the cell control.
Table 2
Reactivity of the mAbs with the mutated Erns proteins in the immunoblot.
Native and mutated Erns
proteins
mAb HC/TC
Group 1 Group 2 169
126 66 69 56 57 58 61
Alfort/187 Erns þþ þþ þþ þþ þþ þþ þþ þþ
Alfort/187 ErnsQ55P þþ þþ þþ þþ þþ þþ þþ þþ
Alfort/187 ErnsA102T þ þ þ þ þ þ þ þþ
Alfort/187 ErnsA107D þ þ þ     þþ
Alfort/187 ErnsA102T/A107Q        þþ
CSF0849 Erns        þþ
CSF0849 ErnsT102A þ þ þ     þþ
CSF0849 ErnsD107A þ þ þ þ þ þ þ þþ
CSF0849 ErnsT102A/D107A þþ þþ þþ þþ þþ þþ þþ þþ
NADL Erns        þþ
NADL ErnsT102A þþ   þþ þþ þþ þþ þþ
NADL ErnsQ105P        þþ
NADL ErnsD107A        þþ
NADL ErnsT102A/D107A þþ þþ þþ þþ þþ þþ þþ þþ
Non-transfected cells        
þþ, strong reactivity; þ , moderate reactivity;  , no reactivity.
D. Meyer et al. / Virology 433 (2012) 45–5448mAb HC/TC169 was excluded from the analysis since it was
considered to be not speciﬁc for CSFV during the preceding
experiments. Control experiments using pestivirus antibody-negative serum and an E2-speciﬁc mAb demonstrated the speciﬁc
interaction of antibodies and membrane-bound peptides (data not
shown). The consensus aa sequences of peptides reacting with the
mAbs form ten separate motifs along the Erns protein, namely
19AMYLRGISR27, 31GIWPEKICK39, 64TNYTCCKLQ72, 73RHEWNKHGW81,
88DPWIQLMNR96, 121DVNVVTQAR129, 136TGCKKG141, 154PCNFNV-
SVE162, 199RVTSWL204, and 213KRLEGRSKTW222 (Fig. S1, Fig. 4). The
CSFV antibody-positive sera recognized nine out of these ten motifs
with exception of 154PCNFNVSVE162 (Fig. S2, Fig. 4). To further
investigate the CSFV speciﬁcity and the potential cross-reactivity of
the identiﬁed peptide sequences, the peptide array was probed with
antisera containing BVDV- and BDV-speciﬁc antibodies (Fig. S3,
Fig. 4). The binding of these antibodies to individual peptide spots
was compared with the binding pattern of CSFV-speciﬁc antibodies.
From the ten previously deﬁned epitopes nine displayed cross-
reactivity with BVDV-speciﬁc antisera and six reacted with antibodies
raised against BDV. All ﬁndings are summarized in Fig. 4. The location
of the ten linear motifs on the full length Erns protein is indicated in
Fig. 2.Discussion
The aim of the present study was to gain new insights into the
antigenic structure of the Erns protein in order to identify CSFV-
speciﬁc antigenic regions which might be important for the
development of Erns-based diagnostic tests. For this purpose, the
binding sites of seven Erns-speciﬁc mAbs were investigated using
different mapping techniques.
During initial experiments, the reactivity of the mAbs was
analyzed by immunoblot under reducing and non-reducing condi-
tions. It could be shown, that after reduction of inter- and
intramolecular disulﬁde bridges the reactivity of the mAbs was
abolished which indicates that the formation of disulﬁde bridges is
an important feature for antibody recognition. To allow an efﬁcient
binding of the CSFV Erns-speciﬁc antibodies, it is therefore required
to present the antigenic epitope in a correct conformation.
To explore the discontinuous antibody binding sites, chimeric
pestivirus proteins in which different parts of the Alfort/187 Erns were
replaced by the corresponding parts of the NADL Erns were used. The
chimeric proteins were expected to fold into their required con-
formation since the four stabilizing intramolecular disulﬁde bridges of
the Erns protein are conserved among pestiviruses (Langedijk, 2002).
The CSFV-speciﬁcmAbs were able to bind the AR4, AR6, AR7, and AR8
chimera, which are identical in the CSFV Erns sequence between aa 55
to 110. Consequently, this region contains aa which are important for
antibody binding. This could be conﬁrmed by the signiﬁcant loss of
antibody reactivity with the AR5 chimera that lacks this speciﬁc
region. The immunodominant region was found to be in accordance
with the antigenic region AR1 (aa 65–145) and partially with the
antigenic region AR2 (aa 84–160) which were detected in previous
studies using anti-CSFV sera and truncated Erns proteins (Lin et al.,
2005; Lin et al., 2004).
To further analyze the inﬂuence of individual aa on the binding
of antibodies, site-directed mutagenesis based on naturally occur-
ring variations within residues 55 to 110 was performed. Analysis
of the reactivity of mAbs with the different Erns exchange mutants
demonstrated that aa 102 and 107 of the Erns protein have a
crucial inﬂuence on the formation of antigen antibody complexes.
However, these aa may not necessarily be essential contact
components of the epitope. The interaction with antibodies may
be inﬂuenced by changes in the structure of the antigen induced
by the mutation. It has previously been shown, that residues in
the vicinity of the proper epitope sequence may interfere with the
folding of the epitope or may inﬂuence the binding of antibodies
due to their physical or biochemical properties (Appel et al., 1990;
Fig. 4. Amino acid sequences of 15-mer peptides and their reactivity with antibodies. The library was probed with: (i) CSFV Erns-speciﬁc monoclonal antibodies HC/TC69,
HC/TC57, HC/TC126, HC/TC61, HC/TC58, HC/TC56, and HC/TC66; (ii) three CSFV-speciﬁc antisera raised against C-strain Riems and challenge strain Koslov (Ko 1 and Ko 2)
or Eystrup (Eyst), respectively; (iii) one BVDV-1 NADL speciﬁc antisera, and (iv) two BDV-speciﬁc antisera raised against strain S137/4 or Frijters, respectively. Intensity
values were quantiﬁed using the Odyssey Software program and normalized to percentage reactivity values. Therefore always the peptide spot with the highest calculated
intensity value on the membrane was arbitrarily set at 100% reactivity.
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could be responsible for keeping the actual epitope in its proper
position and orientation.
In order to evaluate ﬁne speciﬁcities of the mAbs for distinct
epitope motifs, an overlapping peptide library was used. This
technique was chosen since overlapping peptides have been
successfully used in previous studies to map not only linear, but
also discontinuous epitopes, that are recognized by mAbs or by
polyclonal sera (Beattie et al., 1996; Martens et al., 1995;
Posthumus et al., 1990; Reineke et al., 2001; Valle et al., 1999).
In addition to the screening of the mAbs, the CSFV Erns peptide
library was used to investigate the reactivity of polyclonal sera raised
against non-homologous CSFV strains. The recognition pattern for the
seven CSFV Alfort/187 Erns- speciﬁc mAbs and the three different
CSFV-speciﬁc antisera was similar (Fig. 4, Figs. S1 and S2). Based on
these results, it was assumed that aa sequences shared by the
interacting peptides are epitope motifs generally important for the
binding of CSFV-speciﬁc antibodies. Thus, their speciﬁcity is not
unique to the mAbs raised against CSFV Alfort/187.
As shown in Figs. S1–S3, antibodies bound to several separated
stretches of aa on the peptide array, with only three of the
identiﬁed motifs located within aa 55 to 110. This observation
indicated that these motifs might represent different parts of one
discontinuous epitope of the mAbs, rather than individual linear
epitopes. In this type of epitope, the key residues for antibody
binding are distributed over separate regions along the linear
protein sequence, which are only brought together upon folding
of the protein. This implies, that the binding of antibodies is
additionally inﬂuenced by aa sequences that are involved in
maintaining the correct conformation of the epitope. These
hypotheses are supported by the ﬁnding that none of the mAbs
recognized the reduced form of the Erns in immunoblot analyzes.
With regard to the development of an Erns-based DIVA diag-
nostic test, it was crucial to identify epitopes that are speciﬁc for
CSFV. The peptide membrane was therefore incubated with
polyclonal sera raised against BVDV or BDV. As shown in Fig. 4,
most of the detected motifs showed cross-reactivity, which is in
accordance with the high conservation of these sequences among
different pestivirus strains. Only the three motifs 31GIWPEKICK39,
64TNYTCCKLQ72, and 73RHEWNKHGW81 yielded no signiﬁcant
cross-reactivity with BVDV- or BDV-speciﬁc antibodies and could
be considered as truly CSFV-speciﬁc. However, with regard to
putative functional properties, the sequence motifs identiﬁed by
peptide screening yielded some interesting implication: Except
for the N-terminal 19AMYLRGISR27 as well as the two C-terminal
motifs 199RVTSWL204 and 13KRLEGRSKTW222 all the identiﬁed aa
sequences are located within previously deﬁned antigenic regions
on the Erns protein that reacted with antiserum from CSFV-
infected pigs (Lin et al., 2005; Lin et al., 2004). Motif
121DVNVVTQAR129 is in accordance with the linear epitopes
identiﬁed by E. coli surface display of random peptide libraries
and phage display (Christmann et al., 2001; Zhang et al., 2006).
Additionally, the sequences 31GIWPEKICK36 and 64TNYTCCKLQ72
have been deﬁned as parts of critical binding sites for Erns-speciﬁc
mAbs (Lin et al., 2010). The motifs 31GIWPEKICK39 and
73RHEWNKHGW81 are overlapping with the aa stretches that
represent the two RNase active site domains within the Erns
protein of CSFV Alfort/187 (28SLHGIWPE35 and 75EWNKHGWC83,
respectively). These regions are functionally important and there-
fore strongly conserved among pestivirus species and CSFV
strains (Hulst et al., 1994; Windisch et al., 1996). Motifs
199RVTSWL204 and 213KRLEGRSKTW222 are located among resi-
dues 194RQGAARVTSWLGRQLRIAGKRLEGRSK220 that have been
associated with the translocation activity of the Erns protein
(Langedijk, 2002). In another study, peptides comprising those
C-terminal residues were applied as antigens in an ELISA andreacted with CSFV-positive antisera (Langedijk et al., 2001). Even
though the motifs 199RVTSWL204 and 213KRLEGRSKTW222 were
recognized in the peptide array, they are not located within the
antigenic domain identiﬁed by means of chimeric Erns proteins. It
can therefore be assumed, that these sequences are not crucial for
binding the mAbs tested in the present study. This is in accor-
dance with recent results obtained after analyzing the mAb reactivity
with truncated Erns proteins which lack the C-terminal helix (data not
shown). However, these contradictory results further support the
hypothesis that the linear sequence motifs identiﬁed by peptide
screening are part of a discontinuous epitope. Due to the high peptide
density presented on the membrane and the highly sensitive infra-
red-based detection method, the peptide array allows visualizing the
binding of weakly interacting antibodies (Reineke et al., 2002). Thus,
the antibody binding to separate parts of discontinuous epitopes can
be demonstrated, even though the afﬁnity of the antibodies to those
partial sequences is expected to be considerably lower than to the
composite epitope or to a single linear epitope. Accordingly, the
binding of antibodies to sequences that are important for maintaining
a correct conformation of the epitope may be detected.
Finally, the antigenic domain was investigated in context of
N-linked glycosylation sites. According to prediction studies
(NetNGlyc 1.0 Server; http://www.cbs.dtu.dk/services/NetNGlyc/)
for the CSFV Alfort/187 Erns the linear determinants
64TNYTCCKLQ72 and 88DPWIQLMNR96 both contain a putative
glycosylation site (65NYT67 and 95NRT97, respectively). However,
since antibodies raised against the wild type Erns protein were
able to bind the non-glycosylated form of the epitopes on the
peptide library, it can be assumed that the critical binding sites
are not inﬂuenced by glycosylation of the protein.
In contrast to the CSFV strain Alfort/187, another putative
glycosylation site was predicted for the Erns of CSF0849 and
BVDV-1 NADL at position 100NLT102, which includes the mutation
site 102. Addition of carbohydrates to this particular region might
interfere with the binding of antibodies raised against the non-
glycosylated form of the epitope. The inﬂuence of glycosylation
on the reactivity with antibodies may be important with regard to
the selection of a suitable expression system, e.g., for ELISA
antigens, and will therefore be investigated in future studies.
In conclusion, the region between aa 55 to 110 on the Erns protein
represents a composite antigenic domain which contains several
primary determinants. Even though aa at positions 102 and 107 play
a crucial role for the binding of antibodies, the results obtained in the
peptide array suggested that the key interactive residues of the
epitope might be located among the aa sequences 64TNYTCCKLQ72,
73RHEWNKHGW81, and 88DPWIQLMNR96. Analysis of the data
showed, that the mAbs HC/TC58, HC/TC56 and HC/TC66 as well as
the CSFV-speciﬁc polyclonal sera bound peptides corresponding to
motifs 73RHEWNKHGW81, and 88DPWIQLMNR96 with the strongest
intensity, indicating their importance as binding sites (Fig. 4, Figs. S1
and S2). Additionally, the motifs contain several aromatic (W, Y) and
charged, hydrophilic (Q, N, T) aa. In previous studies it has been
shown, that such residues often play a critical role within antigenic
determinants (Appel et al., 1990 and references therein). With regard
to CSFV-speciﬁcity, motifs 31GIWPEKICK39, 64TNYTCCKLQ72, and
73RHEWNKHGW81 represented the most promising candidates, since
they showed no cross-reactivity with BVDV- or BDV-speciﬁc antisera
in the peptide array. In order to conﬁrm these epitopes to be
responsible for the binding of CSFV-Erns speciﬁc antibodies, peptides
were synthesized and applied as antigens in an indirect ELISA. Two
peptides, namely 87IDPWIQLMNRTQANLAE103 and 64TNYTCCKLQR-
HEWNKHGWCNW84, were based on the three linear motifs located
within the antigenic domain aa 55 to 110. An additional peptide
17QHAMYLRGISRSLHGIWPEKICKGVPTYL45 contained aa sequences
that showed a high reactivity with CSFV-speciﬁc antisera and a
minimal cross-reactivity with sera raised against BVDV or BDV during
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speciﬁc mAbs, nor the CSFV-speciﬁc polyclonal antisera yielded a
speciﬁc reactivity with the individual peptides (data not shown).
These observations support the hypothesis that the linear sequence
motifs are parts of discontinuous epitopes. Even though, those
separate parts can be detected using the highly sensitive peptide
array technique, they cannot be presented in a correct conformation
on a single peptide. Thus, they are not recognized by the antibodies.
Furthermore, it can be assumed, that the binding of antibodies is
inﬂuenced by scaffolding aa surrounding the individual motifs. Thus,
the crucial contact aa within the antigenic domain cannot be ﬁnally
mapped. For this purpose, future studies employing substitution
analysis with full length Erns proteins would be required.
Taken all together, some critical points concerning the develop-
ment of Erns-based ELISA systems can be pointed out. To ensure an
efﬁcient binding of antibodies, the epitopes have to be presented in a
proper conformation, indicating the use of full-length Erns as optimal
ELISA antigens. It was further shown, that the speciﬁc interaction of
mAbs with the wild type Erns protein is abolished by the substitution
of single aa at positions that display natural variations among
different CSFV strains. These ﬁndings indicate that an ELISA antigen
based on the Erns sequence of a currently circulating CSFV strain
would guarantee an optimal detection of CSFV-speciﬁc antibodies
raised upon infection. Furthermore, an antigen carrying a mutation at
position 102 [X (¼any aa)-alanine] and 107 (X-alanine), might be
detected by the mAbs tested in this study. The mAbs could therefore
be applied as blocking or competing antibodies in a novel ELISA.
In summary, mapping experiments using chimeric proteins
combined with sequence analysis, site-directed mutagenesis, and
screening of an overlapping peptide library represent successful
strategies for analyzing discontinuous epitopes. Binding sites
recognized by seven CSFV Erns-speciﬁc mAbs could be identiﬁed
and further characterized. Even the importance of individual aa
for the functioning of the epitope could be demonstrated. These
ﬁndings provide new insights into the antigenic structure of the
Erns protein of CSFV and are therefore valuable for the develop-
ment of novel diagnostic assays.Materials and methods
Monoclonal antibodies
Mice were immunized ﬁve times intraperitoneally with 0.2 ml
of concentrated CSFV Alfort/187 (108.5 TCID50/ml; TCID50¼tissue
culture infectious dose 50). Virus concentration of infectious
cell culture supernatant was performed using an Amicon cell
(Millipore, Schwalbach, Germany). The immunization interval
was weekly. Three days after the ﬁfth immunization the spleen
was harvested and used for hybridoma production. Hybridomas
were generated as described previously (Peters et al., 1986) by
fusing of FOX-NY myeloma cells with B-cells from spleens of mice
by Robertsonian chromosome translocation 8.12 (Rb 8.12)
(Taggart and Samloff, 1983). For the epitope mapping studies
the mAbs HC/TC126, HC/TC56, HC/TC57, HC/TC58, HC/TC61, HC/
TC66, HC/TC69 were used. In addition, the mAb HC/TC169 as well
as the Erns-speciﬁc mAb BVD/C12 produced against BVDV-1 strain
NADL served as control antibodies (Greiser-Wilke et al., 1991).
For mapping experiments using the overlapping peptide library,
the E2-speciﬁc mAb HC/TC26, generated against CSFV Alfort/187
was used as a negative control (Greiser-Wilke et al., 1990).
Cells, viruses, and nucleotide sequences
BSR-T7/5 cells, a clone of the BHK-21 permanent cell line
stably expressing T7 polymerase under the control of acytomegalovirus promoter (Buchholz et al., 1999) were kindly
provided by Prof. Dr. Conzelmann (Max-von-Pettenkofer-Insti-
tute, Munich, Germany) and were used for viral protein expres-
sion. The cells were maintained in Eagles minimal essential
medium (EMEM, Gibco BRL, Eggenstein, Germany) supplemented
with 5% fetal calf serum (FCS) free of pestiviruses and correspond-
ing antibodies, 1% non-essential aa (PAA Laboratories GmbH,
Pasching, Austria) and 0.5 mg geniticin/ml (PAA Laboratories
GmbH, Pasching, Austria). The BHK-21 cells were cultured at 5%
CO2 and 37 1C. PK-15 cells, a permanent porcine kidney cell line,
were grown in EMEM with 5% FCS. Before infection the cells were
incubated at 37 1C without CO2 and after infection at 5% CO2 and
37 1C.
The CSFV strain CSF0849 (originating from South Africa) was
obtained from the Institute of Virology, University of Veterinary
Medicine, Hannover, Germany.
Nucleotide sequences were obtained from GenBank for CSFV
Alfort/187 (GenBank ID: X87939), CSFV Glentorf (GenBank ID:
U45478), CSFV Paderborn (GenBank ID: AY072924), CSFV strain
Taiwan 84-KS1 (GenBank ID: AY526729), CSFV Uelzen (GenBank
ID: GU324242), CSFV Kanagawa (GenBank ID: JQ411571), Con-
genital Tremor (GenBank ID:JQ411575), CSFV Guatemala (Gen-
Bank ID: JX028200), BVDV CP7 (GenBank ID: AF220247), CSFV
CSF0849 (GenBank ID: JX185721), and BVDV NADL (GenBank ID:
AJ133739). The selected CSFV strains were chosen as representa-
tives of different CSFV genotypes and subgenotypes. The Erns
nucleotide sequences of BDV Gifhorn, BDV S137/4 and BVDV-2
Mu¨nchen were determined at the Institute for Virology and
Immunoprophylaxis (IVI), Mittelha¨usern, Switzerland. The
sequences were deposited under accession numbers GenBank
ID: JQ624677 (BDV Gifhorn), GenBank ID: JQ624678 (BDV S137/
4), and GenBank ID: JQ624679 (BVDV-2 Mu¨nchen).
RNA extraction, reverse transcription, and PCR
Total RNA from cell culture supernatant of CSF0849-infected
PK-15 cells was extracted with the QIAamp Viral RNA Mini Kit
(Qiagen, Hilden, Germany) following the manufacturer’s recom-
mendations. Synthesis of cDNA was performed using random
hexamers (Invitrogen, Carlsbad, CA, USA) and M-MLV reverse
transcriptase (Invitrogen, Carlsbad, CA, USA). Afterwards the Erns
gene was ampliﬁed by PCR using the ThermoStart Mastermix 800
rxn (Thermo Fisher Scientiﬁc, Abgene House, Surrey, UK) and
the oligonucleotides CSFV-Ernsf and CSFV-Ernsr (Table 3). The
same oligonucleotides were used for cycle sequencing by MWG
(Martinsried, Germany).
Generation of chimeric and mutated Erns constructs
Five chimeric Erns proteins (AR4, AR5, AR6, AR7 and AR8) were
used to determine the antigenic region which is important for
antibody binding. Within these chimeric proteins different parts
of the Erns protein of the CSFV strain Alfort/187 were replaced by
the corresponding parts of the Erns protein of the BVDV-1 strain
NADL (Fig. 5). To ensure the correct passage of the protein
through the endoplasmic reticulum the signal peptide sequence
of the vesicular stomatitis virus (VSV) glycoprotein G was used. To
generate the chimeric constructs an overlapping PCR technique
was applied as described previously (Ko¨hl et al., 2004; Ronecker
et al., 2008). Brieﬂy, the gene fragments of the Alfort/187 Erns and
the NADL Erns were ampliﬁed in separate PCR reactions using the
oligonucleotides listed in Table 3. For the ampliﬁcation of the
CSFV Erns fragments a plasmid encoding the signal peptide
sequence of the VSV G protein and the Erns sequence of CSFV
strain Alfort/187 was used (pTM1-Erns). The plasmid pCG1-Erns
encoding the signal peptide sequence of the VSV G protein and
Table 3
Oligonucleotides used to amplify the Erns gene and to amplify deﬁned fragments of the genomes encoding VSV G (GenBank accession no. NC_001560), CSFV Erns (X87939)
and BVDV-1 Erns (AJ133738) for the generation of the chimeric constructs.
Oligonucleotide Sequence Location in the viral genome
CSFV-Ernsf 50-CATGGGCGGTAATAGCAA-30 1131–1148
CSFV-Ernsr 50-GTGTACCATATGTACCCTA-30 1887–1905
VSV-E2 1f 50-TTTTGAATTCATGAAGTGCCTTTTGTACTTAGCC0-3 3078–3101 (VSV G)
AR4-hybrid-f 50-GCCAAGGAGTGCGCAGTCACTTGTAGGTATGAT-30 1493–1504 (CSFV Erns) 1526–1546 (BVDV Erns)
AR4-hybrid-r 50-ACAAGTGACTGCGCACTCCTTGGCCGGAGG-30 1526–1537 (BVDV Erns) 1487–1504 (CSFV Erns)
AR5-hybrid-f 50-CTGAAAGAAATACATGGTATGATGGATGCA-30 1325–1336 (CSFV Erns) 1358–1375 (BVDV Erns)
AR5-hybrid-r 50-TGCATCCATCATACCATGTATTTCTTTCAG-30 1358–1375 (BVDV Erns) 1325–1336 (CSFV Erns)
AR6-hybrid-f 50-ATCTTGTATGGGGAACATGAACGC-30 1664–1675 (CSFV Erns) 1697–1708 (BVDV Erns)
AR6-hybrid-r 50-GCGTTCATGTTCCCCATACAAGAT-30 1697–1708 (BVDV Erns) 1664–1675 (CSFV Erns)
AR7-hybrid-f 50-CTAAAAACAATTCAGGGAATGATGGATGCC-30 1346–1357 (BVDV Erns) 1337–1354 (CSFV Erns)
AR7-hybrid-r 50-GGCATGCATCATTCCCTGAATTGTTTTTAG-30 1337–1354 (CSFV Erns) 1346–1357 (BVDV Erns)
VSV-Erns hybrid-f* 50-ACCATAGTTTTTCCAGAAAATATAACTCAATGGAAC-30 3132–3146 (VSV G) 1175–1195 (CSFV Erns)
VSV-Erns hybrid-r* 50-TTGAGTTATATTTTCTGGAAAAACTATGGTGAACTT-30 1175–1189 (CSFV Erns) 3126–3146 (VSV G)
Alfort/187-Ernsr* 50-TTTTCTCGAGTTAGGCATAGGCACCAAACCAGGTTTT-30 1832–1855 (CSFV Erns)
NADL-Ernsr 50-TTTTCTCGAGTTAAGCGTATGCTCCAAACCACGTCTT-30 1853–1876 (BVDV Erns)
f: forward primer; r: reverse primer; *: CSFV Erns sequence based on Alfort/187. Nucleotide differences (underlined) between CSF0849 and Alfort/187 are silent mutations
not affecting the amino acid sequence.
Fig. 5. Schematic drawing of the chimeric Erns proteins.CSFV Alfort/187 (grey
boxes), BVDV-1 NADL (open gray boxes), signal peptide sequence (black box).
Numbers indicate the amino acid position of the sequence fusion sites.
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fragments of the BVDV-Erns (Ronecker et al., 2008). The puriﬁed
PCR products were mixed in a molar ratio of 1:1 and denatured
for 2 min at 95 1C. The hybridization (for 30 s at 58 1C) of the
fragments was then mediated by overlapping complementary
sequences that were introduced into the PCR fragments by 50
overhangs of the oligonucleotides. Afterwards, the chimeric DNA
was ampliﬁed using Pfu polymerase (Fermentas, International
Inc., Burlington, Canada). The PCR fragments were cleaved with
restriction enzymes EcoRI and XhoI (Fermentas International Inc.,
Burlington, Canada) and ligated into the pCITE (2aþ) plasmid
(Novagene, Merck KGaA, Darmstadt, Germany) using T4 DNA
ligase (Fermentas International Inc., Burlington, Canada). To gen-
erate the construct encoding the CSF0849 Erns in frame with the
signal peptide of the VSV G protein the above described over-
lapping PCR technique and cloning strategy was applied. The Erns
was ampliﬁed using the oligonucleotides VSV-Erns hybrid-f and
Alfort/187-Ernsr (Table 1). For the ampliﬁcation of the signal
peptide sequence of the VSV G protein the oligonucleotides
VSV-E2 1f and VSV-Erns hybrid-r were used (Table 3). Site-
directed mutagenesis was performed using the Quick Change
Mutagenesis Kit (Stratagene, La Jolla, CA, USA) following the
manufacturer’s recommendations.Transfection
BSR-T7/5 cells were grown for 24 h in either 48 well or 6 well
plates (Greiner bio-one, Frickenhausen, Germany) using 1.5104
(48 well) or 7.5105 (6 well) cells per well, respectively. The cells
were then infected with recombinant vaccinia virus MVA-T7
(kindly provided by Prof. Dr. Sutter, Ludwig-Maximilians-Uni-
versita¨t Mu¨nchen, Munich, Germany) to enhance the T7 RNA
polymerase expression, and 2 h later transfected with the respec-
tive plasmids using Lipofectamine 2000 (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s protocol.
Peroxidase-linked antibody assay
The peroxidase-linked antibody assay (PLA) was used to
analyze the binding activity of the mAbs to the Erns protein of
transfected cells. For determination of the mAb reactivity with the
wild type and chimeric Erns proteins the transfected, heat-ﬁxed
cells (4 h at 80 1C) were washed once and then incubated with
200 ml of the individual hybridoma supernatants (dilution 1:2)
per well of 48 well plates. Incubation was performed overnight at
4 1C. Afterwards, a biotinylated anti-mouse antibody (SIGMA,
Saint Louis, USA) diluted 1:200 was added as secondary antibody
conjugate to the cells for 1 h, followed by a 1 h incubation with a
streptavidin-biotinylated peroxidase complex (GE Healthcare,
Little Chalfont Buckinghamshire, UK), diluted 1:200. Between
each step the cells were washed three times. For washing and
all the dilutions mentioned above phosphate-buffered saline
without MgCl2 and Ca2Cl (PBS) with 0.02% (v/v) Tween20 was
used. Finally, the staining substrate consisting of 0.03% (v/v) H2O2
and 0.4% (w/v) 3-amino-9-ethylcarbazole (AEC) in 0.05 M acetate
buffer, pH 5.5, was added for 30 min. The samples were evaluated
by light microscopy.
Immunoblot
Transfected BSR-T7/5 cells were lysed 20 h post transfection in
200 ml NP-40 lysis buffer [50 mM Tris/HCl (pH 7.5), 150 mM NaCl,
0.5% (w/v) sodium desoxycholate, 1% (v/v) NP-40, complete
protease inhibitor (Roche Diagnostics GmbH, Mannheim, Germany)]
per well and analyzed by immunoblot under non-reducing conditions
[2 sample buffer: 62.5 mM Tris (pH 6.8), 2% (w/v) SDS, 10% (v/v)
Glycerin, 0.01% (w/v) phenol red, 0.01% (w/v) bromphenol blue].
Analysis under reducing conditions was performed using sample
buffer containing 100mMDTT. Proteins (3 mg or 7.5 mg per slot) were
Table 4
Polyclonal sera used for screening of the CSFV Erns peptide library.
Speciﬁcity Inoculum Sampling timepoint NPLAa titer CSFV-E2 ELISA CSFV-Erns ELISA
CSFV Pre-immunization 0 dpv neg neg neg
C-strain Riems, CSFV Koslov 14 dpv (Ko 1) 116 dpv 4640 pos pos
C-strain Riems, CSFV Koslov 14 dpv (Ko 2) 130 dpv 4640 pos pos
C-strain Riems, CSFV Eystrup 23 dpv (Eyst) 47 dpv 226 pos pos
BVDV BVDV NADL 34 dpi 40 neg false pos
BDV BDV S137/4 34 dpi 240 neg neg
BDV Frijters 34 dpi 240 neg neg
a NPLA titers against against CSFV strain Alfort/187 for CSFV-speciﬁc antisera, or against the respective homologous virus strain for BVDV- and BDV-speciﬁc samples,
expressed as ND50.
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10% (v/v) acrylamide resolving gels and transferred to PVDF mem-
branes (Millipore Corporation, Bedford, MA, USA). The blots were
blocked for 1 h in TBS–Tween [Tris-buffered saline: 100mM Tris,
100 mM NaCl, pH 7.5 containing 0.02% (v/v) Tween20] and 2% of the
ECL AdvancedTM blocking agent (GE Healthcare, Little Chalfont
Buckinghamshire, UK). Then they were incubated with hybridoma
supernatant of each mAb (diluted 1:2 in the 2% ECL AdvancedTM
blocking agent-TBS–Tween), followed by incubation with horseradish
peroxidase-conjugated anti-mouse antibody (Dako Denmark A/S,
Glostrup, Denmark), diluted 1:2000 in TBS–Tween. Proteins were
visualized using the BM Chemiluminescence Western Blotting Sub-
strate (Roche Diagnostics GmbH, Mannheim, Germany) or the ECL
Advance Western Blotting Detection Kit (GE Healthcare, Little Chal-
font Buckinghamshire, UK). The monoclonal anti-a-tubulin (diluted
1:4500 in PBS-0.02% Tween20; SIGMA, Saint Louis, USA) was used as
a loading control.
Peptide libraries
A synthetic peptide array for CSFV Erns was prepared by jpt
Peptide Technologies GmbH (Berlin, Germany) using the SPOT
technology (Frank, 2002). Based on the genomic sequence of CSFV
strain Alfort/187 (GenBank ID: X87939) the entire sequence of the
Erns protein was synthesized as a library of 72 peptide spots each
containing peptides of 15 aa in length with 12 residues overlapping
with neighboring peptides. The peptides were covalently bound to a
cellulose-PEG-membrane (Whatman, Maidstone, UK) at the C-termi-
nus and supplied with an acetylated N-terminus.
Polyclonal antisera for library screening
Three CSFV-, one BVDV- and one BDV-antibody-positive sera
were obtained during animal experiments at the IVI. An addi-
tional antiserum raised against BDV strain Frijters was provided
by the Institute of Virology, University of Veterinary Medicine,
Hannover, Germany. A pestivirus antibody-negative pre-immuni-
zation serum collected at the IVI was used as a control. All sera
were tested by neutralization test (NPLA, according to the OIE
manual for diagnostic tests), E2-speciﬁc (Moser et al., 1996) and
Erns-speciﬁc ELISA (PrioCHECK Erns ELISA, Prionics, Schlieren,
Switzerland). An overview of the sera is presented in Table 4.
Peptide library screening
Before use, the dry membrane was rinsed in methanol and
washed in TBS (Tris buffered saline 1 : 50 mM Tris, 137 mM
NaCl, 2.7 mM KCl, pH 8.0). Consecutively, the membrane was
blocked for 2 h using Odyssey Western Blotting Buffer (LI-COR
Biosciences, Bad Homburg, Germany) diluted 1:2 in TBS.
For experiments with polyclonal antisera the peptide mem-
brane was incubated for 3 h with the individual sera diluted1:10,000. To detect captured antibodies the membrane was ﬁrst
incubated for 2 h with a biotinylated anti-swine IgG conjugate
(Santa Cruz Biotechnology Inc., Heidelberg, Germany), and sub-
sequently for 1 h with IRDye 800CW-conjugated streptavidin
(LI-COR Biosciences, Bad Homburg, Germany), both diluted
1:100000. Cell culture supernatant of the mAbs was diluted 1:5
and added to the membrane for 3 h. Subsequently, the membrane
was incubated with an IRDye 800CW-labeled anti-mouse IgG
secondary antibody (LI-COR Biosciences, Bad Homburg, Ger-
many), diluted 1:100000. As ﬁnal step the membrane was washed
with TBS. Analysis and quantiﬁcation of peptide-bound antibodies
was carried out using the Odyssey Infrared Imaging System
(LI-COR Biosciences, Bad Homburg, Germany) according to the
manufacturer’s instructions. All dilutions mentioned above were
done in Odyssey Western Blotting Buffer (LI-COR Biosciences, Bad
Homburg, Germany) diluted 1:2 with TBS and the incubation
steps were performed at room temperature.
In order to reuse the peptide library, the membrane was
regenerated after each incubation by washing in deionized water
followed by four washing steps of 30 min at 50 1C in regeneration
buffer (62.5 mM Tris, 2% (w/v) SDS, 100 mM 2-b-mercaptoetha-
nol, pH 6.7). The membrane was then washed in PBS 10 buffer
(92 mM Na2HPO412H2O, 16 mM NaH2PO412H2O, 1.5 M NaCl,
pH 7.2), followed by rinsing in TBS supplemented with 0.05% (v/v)
Tween20. Successful removal of peptide-bound antibodies was
conﬁrmed by scanning the membrane with the Odyssey Infrared
Imaging System. Between the incubation experiments the mem-
brane was stored in TBS at 4 1C.Acknowledgments
We thank Sabine Schroeder for providing the BDV-speciﬁc
antiserum and Alexander Postel for his advice and the critical
reading of the manuscript.
The research leading to these results has received funding from
the European Community’s Seventh Framework (FP7/2007–2013)
under grant agreement no. 227003 CP-FP (CSFV_goDIVA).Appendix A. Supporting information
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.virol.2012.06.029.References
Appel, J.R., Pinilla, C., Niman, H., Houghten, R., 1990. Elucidation of discontinuous
linear determinants in peptides. J. Immunol. 144, 976.
Beattie, J., Shand, J.H., Flint, D.J., 1996. An immobilised peptide array identiﬁes
antibodies to a discontinuous epitope in the extracellular domain of the
bovine growth hormone receptor. Eur. J. Biochem. 239, 479–486.
D. Meyer et al. / Virology 433 (2012) 45–5454Buchholz, U.J., Finke, S., Conzelmann, K.K., 1999. Generation of bovine respiratory
syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus
replication in tissue culture, and the human RSV leader region acts as a
functional BRSV genome promoter. J. Virol. 73, 251–259.
Christmann, A., Wentzel, A., Meyer, C., Meyers, G., Kolmar, H., 2001. Epitope
mapping and afﬁnity puriﬁcation of monospeciﬁc antibodies by Escherichia coli
cell surface display of gene-derived random peptide libraries. J. Immunol.
Methods 257, 163–173.
Clavijo, A., Lin, M., Riva, J., Mallory, M., Lin, F., Zhou, E.M., 2001. Development of a
competitive using a truncated E2 recombinant protein as antigen for detection
of antibodies to classical swine fever virus. Res. Vet. Sci. 70, 1–7.
Colijn, E.O., Bloemraad, M., Wensvoort, G., 1997. An improved ELISA for the
detection of serum antibodies directed against classical swine fever virus. Vet.
Microbiol. 59, 15–25.
Commandeur, U., Koenig, R., Manteuffel, R., Torrance, L., Lu¨ddecke, P., Frank, R.,
1994. Location, size, and complexity of epitopes on the coat protein of beet
necrotic yellow vein virus studied by means of synthetic overlapping peptides.
Virology 198, 282–287.
Fetzer, C., Tews, B.A., Meyers, G., 2005. The carboxy-terminal sequence of the
pestivirus glycoprotein Erns represents an unusual type of membrane anchor. J.
Virol. 79, 11901–11913.
Frank, R., 2002. The SPOT-synthesis technique: synthetic peptide arrays on
membrane supports—principles and applications. J. Immunol. Methods 267,
13–26.
Greiser-Wilke, I., Dittmar, K.E., Liess, B., Moennig, V., 1991. Immunoﬂuorescence
studies of biotype-speciﬁc expression of bovine viral diarrhoea virus epitopes
in infected cells. J. Gen. Virol. 72, 2015.
Greiser-Wilke, I., Moennig, V., Coulibaly, C.O.Z., Dahle, J., Leder, L., Liess, B., 1990.
Identiﬁcation of conserved epitopes on a hog cholera virus protein. Arch. Virol.
111, 213–225.
Hausmann, Y., Roman-Sosa, G., Thiel, H.J., Ru¨menapf, T., 2004. Classical swine fever
virus glycoprotein Erns is an endoribonuclease with an unusual base speciﬁ-
city. J. Virol. 78, 5507–5512.
Hulst, M.M., Himes, G., Newbigin, E., Moormann, R.J.M., 1994. Glycoprotein E2 of
classical swine fever virus: expression in insect cells and identiﬁcation as a
ribonuclease. Virology 200, 558–565.
Koenig, P., Lange, E., Reimann, I., Beer, M., 2007. CP7_E2alf: a safe and efﬁcient
marker vaccine strain for oral immunisation of wild boar against classical
swine fever virus (CSFV). Vaccine 25, 3391–3399.
Ko¨hl, W., Zimmer, G., Greiser-Wilke, I., Haas, L., Moennig, V., Herrler, G., 2004. The
surface glycoprotein E2 of bovine viral diarrhoea virus contains an intracel-
lular localization signal. J. Gen. Virol. 85, 1101.
Ko¨nig, M., Lengsfeld, T., Pauly, T., Stark, R., Thiel, H.J., 1995. Classical swine fever
virus: independent induction of protective immunity by two structural
glycoproteins. J. Virol. 69, 6479–6486.
Kosmidou, A., Ahl, R., Thiel, H.J., Weiland, E., 1995. Differentiation of classical
swine fever virus (CSFV) strains using monoclonal antibodies against struc-
tural glycoproteins. Vet. Microbiol. 47, 111–118.
Langedijk, J.P.M., 2002. Translocation activity of C-terminal domain of pestivirus
Erns and ribotoxin L3 loop. J. Biol. Chem. 277, 5308–5314.
Langedijk, J.P.M., Middel, W.G.J., Meloen, R.H., Kramps, J.A., De Smit, J.A., 2001.
Enzyme-linked immunosorbent assay using a virus type-speciﬁc peptide
based on a subdomain of envelope protein Erns for serologic diagnosis of
pestivirus infections in swine. J. Clin. Microbiol. 39, 906–912.
Langedijk, J.P.M., Van Veelen, P.A., Schaaper, W.M.M., De Ru, A.H., Meloen, R.H.,
Hulst, M.M., 2002. A structural model of pestivirus Erns based on disulﬁde bond
connectivity and homology modeling reveals an extremely rare vicinal
disulﬁde. J. Virol. 76, 10383–10392.
Lin, M., McRae, H., Dan, H., Tangorra, E., Laverdiere, A., Pasick, J., 2010. High-
resolution epitope mapping for monoclonal antibodies to the structural
protein Erns of classical swine fever virus using peptide array and random
peptide phage display approaches. J. Gen. Virol. 91, 2928–2940.
Lin, M., Trottier, E., Pasick, J., 2005. Antibody responses of pigs to deﬁned Erns
fragments after infection with classical swine fever virus. Clin. Diagn. Lab.
Immunol. 12, 180–186.
Lin, M., Trottier, E., Pasick, J., Sabara, M., 2004. Identiﬁcation of antigenic regions of
the Erns protein for pig antibodies elicited during classical swine fever virus
infection. J. Biochem. (Tokyo) 136, 795–804.Lindenbach, B.D., Rice, C.M., 2001. Flaviviridae: the viruses and their replication.
In: Knipe, D.M., Howly, P.M. (Eds.), Fields Virology, ﬁfth ed. Lippincott
Williams & Wilkins, Philadelphia, pp. 991–1041.
Martens, W., Greiser-Wilke, I., Harder, T.C., Dittmar, K., Frank, R., O¨rvell, C.,
Moennig, V., Liess, B., 1995. Spot synthesis of overlapping peptides on paper
membrane supports enables the identiﬁcation of linear monoclonal antibody
binding determinants on morbillivirus phosphoproteins. Vet. Microbiol. 44,
289–298.
Moormann, R.J.M., Bouma, A., Kramps, J.A., Terpstra, C., De Smit, H.J., 2000.
Development of a classical swine fever subunit marker vaccine and companion
diagnostic test. Vet. Microbiol. 73, 209–219.
Moser, C., Ruggli, N., Tratschin, J.D., Hofmann, M.A., 1996. Detection of antibodies
against classical swine fever virus in swine sera by indirect ELISA using
recombinant envelope glycoprotein E2. Vet. Microbiol. 51, 41–53.
Paton, D.J., McGoldrick, A., Greiser-Wilke, I., Parchariyanon, S., Song, J.Y., Liou, P.P.,
Stadejek, T., Lowings, J.P., Bjo¨rklund, H., Belak, S., 2000. Genetic typing of
classical swine fever virus. Vet. Microbiol. 73, 137–157.
Peters, W., Greiser-Wilke, I., Moennig, V., Liess, B., 1986. Preliminary serological
characterization of bovine viral diarrhoea virus strains using monoclonal
antibodies. Vet. Microbiol. 12, 195–200.
Postel, A., Schmeiser, S., Bernau, J., Meindl-Boehmer, A., Pridotkas, G., Dirbakova, Z.,
Mojzis, M., Becher, P., Elswaiﬁ, S.F., Scarratt, W.F., 2012. Improved strategy for
phylogenetic analysis of classical swine fever virus based on full-length E2
encoding sequences. Vet. Res. 2012, 29.
Posthumus, W.P., Lenstra, J.A., Schaaper, W.M., Van Nieuwstadt, A.P., Enjuanes, L.,
Meloen, R.H., 1990. Analysis and simulation of a neutralizing epitope of
transmissible gastroenteritis virus. J. Virol. 64, 3304–3309.
Reimann, I., Depner, K., Trapp, S., Beer, M., 2004. An avirulent chimeric Pestivirus
with altered cell tropism protects pigs against lethal infection with classical
swine fever virus. Virology 322, 143–157.
Reineke, U., Ivascu, C., Schlief, M., Landgraf, C., Gericke, S., Zahn, G., Herzel, H.,
Volkmer-Engert, R., Schneider-Mergener, J., 2002. Identiﬁcation of distinct
antibody epitopes and mimotopes from a peptide array of 5520 randomly
generated sequences. J. Immunol. Methods 267, 37–51.
Reineke, U., Volkmer-Engert, R., Schneider-Mergener, J., 2001. Applications of
peptide arrays prepared by the SPOT-technology. Curr. Opin. Biotechnol. 12,
59–64.
Ronecker, S., Zimmer, G., Herrler, G., Greiser-Wilke, I., Grummer, B., 2008.
Formation of bovine viral diarrhea virus E1–E2 heterodimers is essential for
virus entry and depends on charged residues in the transmembrane domains.
J. Gen. Virol. 89, 2114–2121.
Ru¨menapf, T., Unger, G., Strauss, J.H., Thiel, H.J., 1993. Processing of the envelope
glycoproteins of pestiviruses. J. Virol. 67, 3288–3294.
Schneider, R., Unger, G., Stark, R., Schneider-Scherzer, E., Thiel, H.J., 1993.
Identiﬁcation of a structural glycoprotein of an RNA virus as a ribonuclease.
Science 261, 1169.
Taggart, R.T., Samloff, I.M., 1983. Stable antibody-producing murine hybridomas.
Science 219, 1228.
Tews, B.A., Meyers, G., 2007. The pestivirus glycoprotein Erns is anchored in plane
in the membrane via an amphipathic helix. J. Biol. Chem 282, 32730–32741.
Valle, M., Munoz, M., Kremer, L., Valpuesta, J.M., Martinez-A, C., Carrascosa, J.L.,
Albar, J.P., 1999. Selection of antibody probes to correlate protein sequence
domains with their structural distribution. Protein Sci. 8, 883–889.
Weiland, E., Ahl, R., Stark, R., Weiland, F., Thiel, H.J., 1992. A second envelope
glycoprotein mediates neutralization of a pestivirus, hog cholera virus. J. Virol.
66, 3677–3682.
Weiland, E., Stark, R., Haas, B., Ru¨menapf, T., Meyers, G., Thiel, H.J., 1990. Pestivirus
glycoprotein which induces neutralizing antibodies forms part of a disulﬁde-
linked heterodimer. J. Virol. 64, 3563–3569.
Windisch, J.M., Schneider, R., Stark, R., Weiland, E., Meyers, G., Thiel, H.J., 1996.
RNase of classical swine fever virus: biochemical characterization and inhibi-
tion by virus-neutralizing monoclonal antibodies. J. Virol. 70, 352–358.
Zhang, F., Yu, M., Weiland, E., Morrissy, C., Zhang, N., Westbury, H., Wang, L.F.,
2006. Characterization of epitopes for neutralizing monoclonal antibodies to
classical swine fever virus E2 and Erns using phage-displayed random peptide
library. Arch. Virol. 151, 37–54.
